From: Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer
Median cfDNA level copies per ml (median,interquartile range) | P value | Mutant copies per ml (median,interquartile range) | P value | Mutant allele fraction % | P value | ctDNA detection | P value | |
---|---|---|---|---|---|---|---|---|
Age | ||||||||
Below 60 | 184,370 (105,485–264,285) | 0.796 | 370 (185–745) | 1 | 0.2 | 0.793 | 2/3 (67%) | 1 |
Above 60 | 56,330 (43,245–70,015) | 60 (15–1395) | 0.115 | 4/6 (67%) | ||||
Pathology subtype | ||||||||
Endometroid | 64,060 (/) | 0.42 | 60 (/) | 0.467 | 0.09 | 0.568 | 1/1 (100%) | 0.446 |
Clear cell | 693,400 (/) | 1840 (/) | 2.65 | 1/1 (100%) | ||||
Serous | 45,030 (36,615–150,427.5) | 215(15–932.5) | 0.17 | 4/6 (67%) | ||||
Dedifferentiated | 72,000 (/) | 0 (/) | 0 | 0/1 (0%) | ||||
FIGO stage | ||||||||
I–II | 38,230 (32,900–49,095) | 0.05 | 0 (0–15) | 0.017 | 0.07 | 0.025 | 1/4 (25%) | 0.025 |
III–IV | 184,370 (64,060–344,200) | 1120 (370–1840) | 2.65 | 5/5 (100%) | ||||
Tumor size | ||||||||
< = 5 cm | 52,760 (37,745–94,137.5) | 0.327 | 60 (45–137.5) | 0.453 | 0.115 | 0.455 | 3/4 (75%) | 0.655 |
> 5 cm | 72,000 (48,600–344,200) | 1120 (0–1840) | 2.65 | 3/5 (60%) | ||||
Depth of invasion | ||||||||
Superficial | 38,230 (32,900–77,187.5) | 0.086 | 30 (0–137.5) | 0.169 | 0.07 | 0.213 | 2/4 (50%) | 0.371 |
Deep | 72,000 (64,060–344,200) | 1120 (370–1840) | 2.65 | 4/5 (80%) | ||||
Node positive | ||||||||
Yes | 184,370 (64,060–344,200) | 0.05 | 1120 (370–1840) | 0.017 | 2.65 | 0.025 | 5/5 (100%) | 0.025 |
No | 38,230 (32,900–49,095) | 0 (0–15) | 0.07 | 1/4 (25%) | ||||
LVSI | ||||||||
Yes | 128,185 (54,450–304,242.5) | 0.142 | 745 (92.5–1660) | 1 | 1.425 | 1 | 2/3 (67%) | 0.655 |
No | 41,460 (38,230–52,760) | 60 (30–60) | 0.09 | 4/6 (67%) | ||||
Involvement of lower uterine segment | ||||||||
Yes | 68,030 (52,465–276,150) | 0.439 | 590 (15–1660) | 0.51 | 1.37 | 0.599 | 2/3 (67%) | 1 |
No | 41,460 (38,230–112,915) | 60 (30–215) | 0.14 | 4/6 (67%) |